|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.95 USD | +2.12% |
|
+5.22% | +12.29% |
| Capitalization | 1.7B 1.45B 1.35B 1.27B 2.35B 156B 2.51B 15.49B 6.13B 73.61B 6.38B 6.25B 269B | P/E ratio 2026 * |
21x | P/E ratio 2027 * | 17.3x |
|---|---|---|---|---|---|
| Enterprise value | 2.25B 1.92B 1.78B 1.67B 3.1B 206B 3.32B 20.47B 8.1B 97.26B 8.43B 8.25B 355B | EV / Sales 2026 * |
1.53x | EV / Sales 2027 * | 1.42x |
| Free-Float |
49.93% | Yield 2026 * |
1.14% | Yield 2027 * | 1.14% |
Last Transcript: Phibro Animal Health Corporation
| 1 day | +2.12% | ||
| 1 week | +5.22% | ||
| Current month | +12.29% | ||
| 1 month | +12.62% | ||
| 3 months | +1.21% | ||
| 6 months | +43.96% | ||
| Current year | +12.29% |
| 1 week | 40.02 |  | 42.22 |
| 1 month | 36.47 | | 42.22 |
| Current year | 36.47 | | 42.22 |
| 1 year | 16.16 | | 46.42 |
| 3 years | 9.4 | | 46.42 |
| 5 years | 9.4 | | 46.42 |
| 10 years | 9.4 | | 54.62 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jack Bendheim
CEO | Chief Executive Officer | 79 | 01/03/2014 |
Glenn David
DFI | Director of Finance/CFO | 55 | 09/02/2024 |
| Chief Tech/Sci/R&D Officer | 50 | 01/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Jack Bendheim
CHM | Chairman | 79 | 01/05/2002 |
Daniel Bendheim
BRD | Director/Board Member | 54 | 01/11/2013 |
E. Corcoran
BRD | Director/Board Member | 79 | 01/05/2008 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +5.81% | 0.33% | 20 M€ | |
| +6.68% | 0.32% | 30 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.12% | +5.22% | +95.03% | +173.65% | 1.7B | |
| +1.49% | -0.60% | -25.34% | -23.64% | 55.12B | |
| +0.58% | -0.57% | +101.83% | +84.37% | 12.07B | |
| -0.42% | +4.11% | -19.83% | +6.83% | 4.15B | |
| -2.32% | -0.83% | +16.59% | +32.78% | 3.51B | |
| -2.21% | -0.06% | +174.44% | +65.45% | 2.71B | |
| -0.90% | -10.76% | -28.43% | -6.06% | 1.66B | |
| +0.10% | +2.75% | +10.59% | +2.59% | 1.34B | |
| -1.76% | +5.93% | +33.17% | -34.91% | 1.23B | |
| +0.36% | -3.26% | +22.96% | -4.05% | 1.15B | |
| Average | -0.30% | +0.57% | +38.10% | +29.70% | 8.46B | |
| Weighted average by Cap. | +0.87% | -0.23% | +5.64% | +3.28% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.47B 1.25B 1.16B 1.09B 2.02B 134B 2.17B 13.35B 5.28B 63.45B 5.5B 5.38B 232B | 1.51B 1.29B 1.2B 1.13B 2.09B 139B 2.24B 13.79B 5.46B 65.53B 5.68B 5.56B 239B |
| Net income | 81.56M 69.74M 64.74M 60.71M 113M 7.47B 121M 743M 294M 3.53B 306M 300M 12.9B | 99.16M 84.79M 78.71M 73.81M 137M 9.08B 147M 903M 357M 4.29B 372M 364M 15.68B |
| Net Debt | 546M 467M 434M 407M 755M 50.05B 808M 4.98B 1.97B 23.65B 2.05B 2.01B 86.4B | 448M 383M 355M 333M 618M 40.99B 662M 4.08B 1.61B 19.37B 1.68B 1.64B 70.77B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/01/26 | 41.95 $ | +2.12% | 220,110 |
| 20/01/26 | 41.08 $ | +0.02% | 165,333 |
| 16/01/26 | 41.07 $ | +2.52% | 218,929 |
| 15/01/26 | 40.06 $ | +0.48% | 176,998 |
| 14/01/26 | 39.87 $ | -1.46% | 194,182 |
Delayed Quote Nasdaq, January 22, 2026 at 12:00 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PAHC Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition